Bronchopulmonary Dysplasia - Pipeline Review, H2 2016

Date: August 24, 2016
Pages: 64
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BD2D67C7DB9EN
Leaflet:

Download PDF Leaflet

Bronchopulmonary Dysplasia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Bronchopulmonary Dysplasia - Pipeline Review, H2 2016’, provides an overview of the Bronchopulmonary Dysplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia
  • The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects
  • The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Bronchopulmonary Dysplasia Overview
Therapeutics Development
Pipeline Products for Bronchopulmonary Dysplasia - Overview
Bronchopulmonary Dysplasia - Therapeutics under Development by Companies
Bronchopulmonary Dysplasia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bronchopulmonary Dysplasia - Products under Development by Companies
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
Airway Therapeutics LLC
Chiesi Farmaceutici SpA
Insmed Incorporated
MediPost Co., Ltd.
Meridigen Biotech Co., Ltd.
Syntrix Biosystems, Inc.
Therabron Therapeutics, Inc.
Bronchopulmonary Dysplasia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pneumostem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-908 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapies for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchopulmonary Dysplasia - Dormant Projects
Bronchopulmonary Dysplasia - Discontinued Products
Bronchopulmonary Dysplasia - Product Development Milestones
Featured News & Press Releases
Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants
May 03, 2016: MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease
Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth
Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform
Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate
Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial
Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform
Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program
May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia
Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial
Jul 29, 2014: Lung disease stem cell drug designated ‘orphan drug in development stage’
Feb 06, 2014: Stem cells to treat lung disease in preterm infants
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H2 2016
Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H2 2016
Bronchopulmonary Dysplasia - Pipeline by Insmed Incorporated, H2 2016
Bronchopulmonary Dysplasia - Pipeline by MediPost Co., Ltd., H2 2016
Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co., Ltd., H2 2016
Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems, Inc., H2 2016
Bronchopulmonary Dysplasia - Pipeline by Therabron Therapeutics, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Bronchopulmonary Dysplasia - Dormant Projects, H2 2016
Bronchopulmonary Dysplasia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Bronchopulmonary Dysplasia - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 63 pages
Cervical Dysplasia - Pipeline Review, H1 2015 US$ 1,600.00 May, 2015 · 56 pages
Bronchopulmonary Dysplasia - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Cerebral Palsy - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 46 pages

Ask Your Question

Bronchopulmonary Dysplasia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: